title: Diminished G1 checkpoint after gamma-irradiation and altered cell cycle regulation by insulin-like growth factor II overexpression.
abstract: High levels of insulin-like growth factor II (IGFII) mRNA expression are detected in many human tumors of different origins including rhabdomyosarcoma, a tumor of skeletal muscle origin. To investigate the role of IGFII in tumorigenesis, we have compared the mouse myoblast cell line C2C12-2.7, which was stably transfected with human IGFII cDNA and expressed high and constant amounts of IGFII, to a control cell line C2C12-1.1. A rhabdomyosarcoma cell line, RH30, which expresses high levels of IGFII and contains mutated p53, was also used in these studies. IGFII overexpression in mouse myoblast C2C12 cells causes a reduced cycling time and higher growth rate. After gamma-irradiation treatment, C2C12-1.1 cells were arrested mainly in G0/G1 phase. However, C2C12-2.7 and RH30 cells went through a very short G1 phase and then were arrested in an extended G2/M phase. To verify further the effect of IGFII on the cell cycle, we developed a Chinese hamster ovary (CHO) cell line with tetracycline-controlled IGFII expression. We found that CHO cells with high expression of IGFII have a shortened cycling time and a diminished G1 checkpoint after treatment with methylmethane sulfonate (MMS), a DNA base-damaging agent, when compared with CHO cells with very low IGFII expression. It was also found that IGFII overexpression in C2C12 cells was associated with increases in cyclin D1, p21, and p53 protein levels, as well as mitogen-activated protein kinase activity. These studies suggest that IGFII overexpression shortens cell cycling time and diminishes the G1 checkpoint after DNA damage despite an intact p53/p21 induction. In addition, IGFII overexpression is also associated with multiple changes in the levels and activities of cell cycle regulatory components following gamma-irradiation. Taken together, these changes may contribute to the high growth rate and genetic alterations that occur during tumorigenesis.
authors.affiliation: Molecular Oncology Section, National Institutes of Health, Bethesda, Maryland 20892-1928, USA.
authors.forename: L
authors.initials: L
authors.lastname: Zhang
authors.forename: M
authors.initials: M
authors.lastname: Kim
authors.forename: Y H
authors.initials: YH
authors.lastname: Choi
authors.forename: B
authors.initials: B
authors.lastname: Goemans
authors.forename: C
authors.initials: C
authors.lastname: Yeung
authors.forename: Z
authors.initials: Z
authors.lastname: Hu
authors.forename: S
authors.initials: S
authors.lastname: Zhan
authors.forename: P
authors.initials: P
authors.lastname: Seth
authors.forename: L J
authors.initials: LJ
authors.lastname: Helman
mesh_terms: D000818:Animals; D016466:CHO Cells; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000378:metabolism; D018797:Cell Cycle Proteins / Q000378:metabolism; D002455:Cell Division; D006224:Cricetinae; D018844:Cyclin-Dependent Kinases / Q000378:metabolism; D004249:DNA Damage; D016193:G1 Phase / Q000502:physiology*; D005720:Gamma Rays; D006801:Humans; D007335:Insulin-Like Growth Factor II / Q000378:metabolism / Q000502:physiology*; D051379:Mice; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D018797:Cell Cycle Proteins; D007335:Insulin-Like Growth Factor II; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D018844:Cyclin-Dependent Kinases